Unicycive Therapeutics (NASDAQ:UNCY) Price Target Lowered to $15.00 at HC Wainwright

Unicycive Therapeutics (NASDAQ:UNCY) had its price objective cut by stock analysts at HC Wainwright from $22.00 to $15.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 218.47% from the stock’s previous close.

A number of other research firms have also weighed in on UNCY. Wall Street Zen lowered Unicycive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. B. Riley Financial reissued a “buy” rating and set a $22.00 price objective on shares of Unicycive Therapeutics in a research note on Tuesday. Weiss Ratings upgraded shares of Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 9th. Guggenheim reaffirmed a “buy” rating and issued a $37.00 target price (down from $40.00) on shares of Unicycive Therapeutics in a research note on Wednesday, May 13th. Finally, Benchmark reiterated a “speculative buy” rating and set a $18.00 price target (up from $15.00) on shares of Unicycive Therapeutics in a report on Tuesday, June 2nd. Five research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Unicycive Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

Unicycive Therapeutics Trading Down 38.8%

Shares of UNCY stock traded down $2.99 during trading hours on Tuesday, hitting $4.71. 15,800,906 shares of the company’s stock were exchanged, compared to its average volume of 849,155. The company has a market capitalization of $129.02 million, a PE ratio of -2.12 and a beta of 1.74. Unicycive Therapeutics has a 12-month low of $3.71 and a 12-month high of $8.74. The business’s 50 day simple moving average is $7.55 and its 200-day simple moving average is $6.84.

Unicycive Therapeutics (NASDAQ:UNCY) last released its earnings results on Tuesday, May 12th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.46) by ($0.08). Equities analysts anticipate that Unicycive Therapeutics will post -0.32 EPS for the current year.

Institutional Trading of Unicycive Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Seven Fleet Capital Management LP acquired a new position in Unicycive Therapeutics in the first quarter valued at approximately $367,000. Bank of America Corp DE lifted its position in shares of Unicycive Therapeutics by 19,327.6% in the first quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after acquiring an additional 29,378 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Unicycive Therapeutics during the 1st quarter worth $161,000. Dimensional Fund Advisors LP acquired a new stake in Unicycive Therapeutics in the 1st quarter valued at about $940,000. Finally, Quadrature Capital Ltd purchased a new position in Unicycive Therapeutics during the fourth quarter worth approximately $226,000. 40.42% of the stock is currently owned by institutional investors and hedge funds.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.